M

MBX Biosciences Inc
NASDAQ:MBX

Watchlist Manager
MBX Biosciences Inc
NASDAQ:MBX
Watchlist
Price: 12.47 USD 1.14% Market Closed
Market Cap: 416.7m USD

Relative Value

There is not enough data to reliably calculate the relative value of MBX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MBX Relative Value
Base Case
Not Available
M
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.5
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-5.5
Industry
21.8
Forward
-4.6
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-6.2
Industry
16.6
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.1
Industry
24
vs History
33
vs Industry
Median 3Y
1.7
Median 5Y
1.7
Industry
2.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2
Industry
12.8
Forward
-1.6
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2
Industry
16.2
Forward
-1.6
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-2.4
Industry
15.1
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-2.4
Industry
17.7
vs History
33
vs Industry
Median 3Y
179.7
Median 5Y
179.7
Industry
1.9

Multiples Across Competitors

MBX Competitors Multiples
MBX Biosciences Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
MBX Biosciences Inc
NASDAQ:MBX
416.8m USD 0 -5.7 -2.2 -2.2
US
Eli Lilly and Co
NYSE:LLY
739.9B USD 15.1 66.6 35.8 39.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375.3B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.1 13.3 15.2
CH
Roche Holding AG
SIX:ROG
206.8B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
190.9B CHF 4.5 18.7 11 14.7
UK
AstraZeneca PLC
LSE:AZN
160.3B GBP 4 28.2 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
203.6B USD 3.2 11.7 8.7 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
144.3B USD 2.3 18.3 7.8 10.9
P/E Multiple
Earnings Growth PEG
US
M
MBX Biosciences Inc
NASDAQ:MBX
Average P/E: 25.6
Negative Multiple: -5.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.6
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
18.7
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
MBX Biosciences Inc
NASDAQ:MBX
Average EV/EBITDA: 433.7
Negative Multiple: -2.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
11
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
M
MBX Biosciences Inc
NASDAQ:MBX
Average EV/EBIT: 1 867.3
Negative Multiple: -2.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.1
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.2
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14.7
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.5
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1